J. Kristensen

Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma.

N. Abildgaard, K. Brixen, E. Eriksen, 2004, Haematologica.

Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum

N. Abildgaard, L. Heickendorff, K. Bendix-Hansen, 1997, British journal of haematology.

Ampicillin‐metronidazole treatment in idiopathic preterm labour: a randomised controlled multicentre trial

J. Langhoff‐Roos, J. Kristensen, H. Borch-Christensen, 1997, British journal of obstetrics and gynaecology.

Lithium induced interstitial nephropathy associated with chronic renal failure. Reversibility and correlation between functional and structural changes.

S. Christensen, P. Ottosen, J. Kristensen, 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

GLP‐1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

J. Holst, P. Hellström, S. Efendić, 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

B. Biemond, A. Inati, Y. Kilinç, 2021, The Lancet. Haematology.

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.

B. Rovin, R. Lafayette, V. Tesar, 2022, Kidney international.

POS-830 NEFECON FOR THE TREATMENT OF IgA NEPHROPATHY IN PATIENTS AT RISK OF PROGRESSING TO END-STAGE RENAL DISEASE: THE NEFIGARD PHASE 3 TRIAL RESULTS

J. Barratt, A. Stone, J. Kristensen, 2021 .

Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre‐treatment levels of S‐ICTP and U‐Ntx are predictive for early progression of the bone disease during standard chemotherapy

N. Abildgaard, K. Brixen, E. Eriksen, 2003, British journal of haematology.

Clinical trial: the glucagon‐like peptide‐1 analogue ROSE‐010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo‐controlled, double‐blind study

P. Hellström, P. Bytzer, H. Schambye, 2009, Alimentary pharmacology & therapeutics.

T1388 GTP-010 As a Therapeutic Tool in IBS Pain Relief: Prospective, Randomized, Placebo-Controlled Study of a GLP-1 Analog

E. Bjornsson, P. Hellström, P. Bytzer, 2008 .

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

B. Rovin, R. Lafayette, V. Tesar, 2023, The Lancet.